Our Focus

Home / Our Focus / Nephropathies

Complement-dependent Nephropathies

For information about our Phase 2 clinical trial in Glomerulopathies (IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis or Dense Deposit Disease), please click on the link below or email us at clinicaltrials@apellis.com:
Phase 2 Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies (DISCOVERY)

IgA nephropathy (IgAN), lupus nephritis, idiopathic membranous nephropathy and C3 glomerulopathy are diseases caused by activation of complement pathways. In all of these diseases, immune complexes (autoantibody- antigen complexes) or C3 are deposited in the portion of the kidney known as the glomeruli, which is responsible for blood filtration. These deposits lead to activation of either all three or two of the three principal pathways of the complement system: classical, lectin and alternative. By targeting C3 at the point of convergence of all three pathways, we believe APL-2 has the potential to prevent C3 activation and C3-mediated inflammatory response responsible for the renal manifestations of injury common to all these diseases.

Apellis logo
© Apellis Pharmaceuticals 2019.